Autopsy report · NCT05325281

CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

“The pharmaceutical funder pulled funding and no longer plans to develop the drug further.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 2 years 8 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Medical College of Wisconsin

Sponsor type

University, hospital or other

Conditions

Pancreas Adenocarcinoma

Interventions

CPI-613® (Dose level -1.0 250 mg/m^2); CPI-613® (Dose level 1.0 500 mg/m^2); CPI-613® (Dose level 2.0 1,000 mg/m^2); CPI-613® (Dose level 3.0 1,500 mg/m^2); CPI-613® Maximum Tolerated Dose (MTD); Gemcitabine

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
  “No longer have funding support to complete the pharmacogenetics component.” (73% match in meaning)
• PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
  “Pharmaceutical collaborator pulled funding.” (70% match in meaning)
• Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
  “Manufacturer is no longer making the drug.” (69% match in meaning)
• Taxotere-Enoxaparin-(ENOXA)-Study
  “The external funding (pharmaceutical company) was stopped and could not be substituded by internal funding.” (68% match in meaning)
• ARTerial EMbolization for haemorrhoIdal Disease (ART.EM.I. Study)
  “Funding no longer available.” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.